Clinical trials: Deleterious EPCAM Gene Mutation

Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

• Active, not recruiting
• Age: 30 to 50 years
• Surgery or procedure

This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer.

Conditions

Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation

Trial name

NCT02760849

Testing

Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment

Where

9 sites in United States

Volunteers

374 people

Sponsor

M.D. Anderson Cancer Center